The Fly | CAMP

Proprietary REGULON-IQ Platform Technology: CAMP4's foundational platform maps RNA networks to systematically identify non-coding RNA targets that regulate gene expression.

Novel RNA Actuator Therapeutic Modality: Pioneers a new class of therapeutics, RNA Actuators, specifically designed to up-regulate gene expression, addressing diseases caused by insufficient protein production.

Broad Applicability Across Genetic Diseases: The platform's ability to modulate gene expression holds potential for treating a wide array of genetic diseases currently lacking effective therapies.

Clinical Development and Success Risk: CAMP's drug candidates are in early stages of development and may not successfully complete clinical trials or obtain marketing approval.

Regulatory Approval Uncertainty Risk: Even if successful in clinical trials, CAMP may not obtain the necessary regulatory approvals from the FDA or similar foreign agencies for its product candidates.

Capital and Future Funding Risk: CAMP has a history of losses and will require substantial additional capital to fund its operations and commercialize any product candidates, which may not be available on acceptable terms or at all.

Charts

Proprietary REGULON-IQ Platform Technology: CAMP4's foundational platform maps RNA networks to systematically identify non-coding RNA targets that regulate gene expression.

Broad Applicability Across Genetic Diseases: The platform's ability to modulate gene expression holds potential for treating a wide array of genetic diseases currently lacking effective therapies.

Clinical Development and Success Risk: CAMP's drug candidates are in early stages of development and may not successfully complete clinical trials or obtain marketing approval.